Results 261 to 270 of about 222,667 (349)
Pharmacokinetic parameters of bictegravir in breastmilk of healthy, lactating volunteers without HIV after a single dose of 50 mg (co‐formulated with emtricitabine 200 mg and tenofovir alafenamide 25 mg) [PDF]
Lena van der Wekken‐Pas +2 more
openalex +1 more source
Doxorubicin (DOX)‐induced cardiotoxicity is a major limitation to its broader clinical application, while cardioprotective interventions often risk reducing the anticancer efficacy of DOX. To address these challenges, this work constructs an EDTA‐functionalized metal–organic framework that enhances tumor therapy and provides efficient cardioprotection ...
Daojing Yuan +8 more
wiley +1 more source
Silicon incorporated tacrine: design, synthesis, and evaluation of biological and pharmacokinetic parameters. [PDF]
Kulkarni AS +10 more
europepmc +1 more source
Relationship between pharmacokinetic parameter and effect of antimicrobial agent.Aminoglycosides.
KYOICHI TOTSUKA
openalex +2 more sources
A Scalable Framework for Comprehensive Typing of Polymorphic Immune Genes from Long‐Read Data
SpecImmune introduces a unified computational framework optimized for long‐read sequencing to resolve over 400 highly polymorphic immune genes. This scalable approach achieves high‐resolution typing, enabling the discovery of cross‐family co‐evolutionary networks and population‐specific diversity.
Shuai Wang +5 more
wiley +1 more source
Randall's plaques (RP) serve as the nidus for calcium oxalate (CaOx) kidney stones. The current study reveals that hydroxyapatite (HAP) crystals activate the THY1–GSK3α/β–β‐catenin axis in renal interstitial fibroblasts (hRIFs), inducing FASLG secretion.
Minghui Liu +14 more
wiley +1 more source
Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506 [PDF]
Abu-Elmagd, K +10 more
core
First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena +5 more
wiley +1 more source

